RemeGen Co., Ltd.

SEHK:9995 Rapporto sulle azioni

Cap. di mercato: HK$11.6b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RemeGen Gestione

Gestione criteri di controllo 3/4

RemeGen's Il CEO è Jianmin Fang, nominato in Oct2008, e ha un mandato di 15.83 anni. la retribuzione annua totale è CN¥ 14.66M, composta da 37% di stipendio e 63% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 11.44% delle azioni della società, per un valore di HK$ 1.49B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 4.3 anni.

Informazioni chiave

Jianmin Fang

Amministratore delegato

CN¥14.7m

Compenso totale

Percentuale dello stipendio del CEO37.0%
Mandato del CEO15.8yrs
Proprietà del CEO11.4%
Durata media del management2.6yrs
Durata media del Consiglio di amministrazione4.3yrs

Aggiornamenti recenti sulla gestione

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Jun 21
Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Recent updates

RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 20
RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price

Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

Jul 22
Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet

Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

Jun 21
Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Apr 04
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

Mar 24
Is RemeGen (HKG:9995) Using Debt In A Risky Way?

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Feb 18
RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

Dec 29
Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 16
RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

Aug 03
Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

Jun 22
Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

May 10
RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

Mar 09
Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

May 04
RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08
RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23
RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Jan 21
We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

Nov 30
Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Oct 16
We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)

Aug 24
A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)

Here's What RemeGen Co., Ltd.'s (HKG:9995) Shareholder Ownership Structure Looks Like

Feb 09
Here's What RemeGen Co., Ltd.'s (HKG:9995) Shareholder Ownership Structure Looks Like

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jianmin Fang rispetto agli utili di RemeGen?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-CN¥2b

Mar 31 2024n/an/a

-CN¥2b

Dec 31 2023CN¥15mCN¥5m

-CN¥2b

Sep 30 2023n/an/a

-CN¥1b

Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥27mCN¥5m

-CN¥999m

Sep 30 2022n/an/a

CN¥276m

Jun 30 2022n/an/a

CN¥231m

Mar 31 2022n/an/a

CN¥174m

Dec 31 2021CN¥8mCN¥4m

CN¥276m

Compensazione vs Mercato: La retribuzione totale di Jianmin ($USD 2.06M ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 629.60K ).

Compensazione vs guadagni: La retribuzione di Jianmin è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Jianmin Fang (61 yo)

15.8yrs

Mandato

CN¥14,658,000

Compensazione

Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. He has been Director, Chief Executive Officer and GM of RemeGen Co. Ltd. and served as its Chief Scientific Officer since October 16, 2008 to 2023 and red...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Weidong Wang
Co-Founder & Executive Chairman10.8yrsCN¥15.15mNessun dato
Jianmin Fang
Co-Founder15.8yrsCN¥14.66m11.44%
CN¥ 1.3b
Shaojing Tong
CFO & Joint Company Secretaryless than a yearCN¥1.25mNessun dato
Ruyi He
Chief Medical Officerno dataCN¥24.01m0.00090%
CN¥ 104.2k
Jian Lin
Executive Directorno dataCN¥1.13mNessun dato
Kaisheng Huang
Chief Operating Officerno dataNessun datoNessun dato
Marie Zhu
Chief Technical Officerno dataNessun datoNessun dato
Zhulun Wang
Chief Scientific Officerno dataNessun datoNessun dato
Daniel Ross
Chief Business Officerless than a yearNessun datoNessun dato
Xiaoming Yang
Chief Manufacturing Officerno dataNessun datoNessun dato
Qingkai Wen
Board Secretary4.3yrsNessun datoNessun dato

2.6yrs

Durata media

61yo

Età media

Gestione esperta: Il team dirigenziale di 9995 è considerato esperto (durata media dell'incarico 2.6 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Weidong Wang
Co-Founder & Executive Chairman10.8yrsCN¥15.15mNessun dato
Jianmin Fang
Co-Founder15.8yrsCN¥14.66m11.44%
CN¥ 1.3b
Ruyi He
Chief Medical Officer4.3yrsCN¥24.01m0.00090%
CN¥ 104.2k
Jian Lin
Executive Director16.1yrsCN¥1.13mNessun dato
Lorne Alan Babiuk
Member of Scientific Advisory Boardno dataCN¥125.00kNessun dato
Gang Pei
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Liqiang Wang
Non-Executive Director4.3yrsNessun dato4.69%
CN¥ 543.2m
Xiaodi Su
Non-Executive Director4.3yrsNessun datoNessun dato
Xianjing Hao
Independent Non-Executive Director4.3yrsCN¥300.00kNessun dato
Guangke Ren
Chairman of the Supervisory Board4.3yrsNessun datoNessun dato
Lan Ma
Independent Non-Executive Director3.2yrsCN¥300.00kNessun dato
Yunjin Chen
Independent Non-Executive Director2.3yrsCN¥300.00kNessun dato

4.3yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 9995 sono considerati esperti (durata media dell'incarico 4.3 anni).